# PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.

> **NCT07428642** · — · COMPLETED · sponsor: **First Affiliated Hospital of Wenzhou Medical University** · enrollment: 168 (actual)

## Conditions studied

- Metastatic Hormone-Sensitive Prostate Cancer
- Prostate Cancer

## Interventions

- **DRUG:** Androgen Deprivation Therapy
- **DRUG:** Apalutamide
- **DRUG:** Enzalutamide
- **DRUG:** Darolutamide
- **DRUG:** Rezvilutamide
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT07428642
- **Lead sponsor:** First Affiliated Hospital of Wenzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-01
- **Primary completion:** 2025-12-03
- **Final completion:** 2025-12-03
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2026-03-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07428642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07428642, "PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07428642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*